Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease

NCT00685646 is registered in ClinicalTrials.gov with Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan as lead sponsor.

NCT NCT00685646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00685646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
January 31, 2014
Enrollment
227 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, prostate cancer